Welcome to our dedicated page for AEMETIS SEC filings (Ticker: AMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AEMETIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AEMETIS's regulatory disclosures and financial reporting.
Aemetis, Inc. director Simon Timothy Alan received a grant of 12,000 shares of Common Stock on January 22, 2026 at $1.54 per share. The award was made under the Aemetis Amended and Restated 2019 Stock Plan as compensation for his service on the Board of Directors.
After this equity grant, he beneficially owns 52,632 shares of Aemetis Common Stock in direct form.
Aemetis director John R. Block received a grant of 12,000 shares of Aemetis common stock on 01/22/2026 at a price of $1.54 per share. The shares were granted under the Aemetis, Inc. Amended and Restated 2019 Stock Plan as compensation for his service on the Board of Directors.
After this award, he beneficially owns 46,330 shares of Aemetis common stock in direct form.
Aemetis, Inc. director Barton Francis P reported receiving a grant of 18,000 shares of Common Stock on January 22, 2026. The award was priced at $1.54 per share and was issued as compensation for service on the Board of Directors under the Aemetis, Inc. Amended and Restated 2019 Stock Plan.
Following this equity grant, Barton Francis P beneficially owns 226,518 shares of Aemetis Common Stock in direct ownership.
Aemetis, Inc. director Lydia I. Beebe reported receiving a grant of common stock as board compensation. On 01/22/2026, she was awarded 14,500 shares of Aemetis common stock at $1.54 per share under the company’s Amended and Restated 2019 Stock Plan. Following this grant, she beneficially owns 214,286 common shares, held directly. The transaction reflects routine equity-based compensation for service on the Board of Directors.
Aemetis, Inc. director Naomi Louise Boness reported a stock grant received for board service. On 01/22/2026 she acquired 12,000 shares of Aemetis common stock at $1.54 per share under the Aemetis, Inc. Amended and Restated 2019 Stock Plan, as compensation for serving on the Board of Directors. Following this grant, she beneficially owned 64,643 common shares held directly.
Aemetis, Inc. approved several governance and capital actions. The board’s committee authorized an annual $350,000 guarantee fee to McAfee Capital LLC, wholly owned by Chairman and CEO Eric A. McAfee, for personal guarantees supporting certain credit facilities and debt obligations, continuing the company’s historical practice.
The committee also granted discretionary cash bonuses to key executives, including $200,000 to Mr. McAfee and $125,000 each to three executive vice presidents, with another executive vice president receiving $50,000. Separately, the board authorized a share repurchase program allowing the company to buy back up to $80 million of common stock over time, with purchases made at management’s discretion and no set end date. The company is also holding a special stockholder meeting to vote on charter amendments to change authorized common and preferred share levels.
Aemetis, Inc. filed its Q3 2025 10‑Q, reporting revenue of $59.2 million for the quarter and a net loss of $23.7 million. For the nine months, revenue was $154.3 million with a net loss of $71.7 million.
Quarterly results reflected softer biodiesel sales in India and a near break‑even gross margin, while SG&A was $8.5 million. Interest and financing costs remained heavy, with quarterly interest expense of $11.9 million and total other debt‑related costs of $3.3 million.
As of September 30, 2025, cash and equivalents were $5.6 million ($8.6 million including restricted), total debt was $353.5 million, and the ABGL Series A preferred units liability was $131.0 million. The company recorded $16.4 million net cash provided by financing year‑to‑date and $(2.5) million net cash used in operations. Shares outstanding were 65.0 million as of September 30, 2025, and 65,568,542 as of October 31, 2025.
ABGL’s Series A preferred redemption deadline was extended to December 31, 2025; if not redeemed, a credit agreement effective January 1, 2026 would replace it at an interest rate equal to the greater of prime + 10.0% or 16.0%.
Aemetis (AMTX) reported that it issued an earnings press release for the three and nine months ended September 30, 2025. The release is furnished as Exhibit 99.1 to a Form 8-K under Item 2.02 and Item 7.01, and is posted on the company’s website. The Form 8-K and Exhibit 99.1 are deemed “furnished” rather than “filed” under the Exchange Act and are not incorporated by reference into any registration statement.
Aemetis, Inc. disclosed that subsidiary Aemetis Biogas LLC (ABGL) executed a Tenth Waiver and Amendment to its Series A Preferred Unit Purchase Agreement with Protair-X Technologies Inc. and Third Eye Capital, effective August 31, 2025. The amendment extends ABGL’s deadline to redeem all outstanding Series A Preferred Units from August 31, 2025 to December 31, 2025 and sets the aggregate redemption price at $118.8 million, which includes a $2 million amendment fee.
If ABGL does not redeem by the new deadline, it will enter a Credit Agreement in substantially the attached form, effective January 1, 2026, maturing September 1, 2026, with interest at the greater of 16.0% or the prime rate plus 10.0%. The agreement would require guarantees from Aemetis, Inc. and certain subsidiaries and grant security interests in the assets of ABGL and the guarantors. Protair-X currently owns 100% of ABGL’s Series A Preferred Units.
Barton Francis P, identified as a director of Aemetis, Inc. (AMTX), reported multiple open-market sales of the issuer's common stock on 08/14/2025. Four sale transactions at a price of $2.5335 per share disposed of 1,300, 12,152, 5,000 and 8,000 shares, totaling 26,452 shares sold. The filings show the reporting person’s beneficial ownership decreased from 233,670 shares pre-sale (as reflected after the first line) to 208,518 shares following the last reported transaction. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.